Studies in recent years show an increase in the incidence of fungal urinary tract infection (UTI). The most common causative agents of fungal UTIs are representatives of the genus Candida. Antifungal therapy is indicated in case of the detection of fungi in the urine of patients with symptoms of UTI, immunocompromised patients, low birth weight newborns, and also before urological surgical interventions. For the treatment of urinary tract candidiasis, the use of drugs of the triazole group – amphotericin B and flucytosine is recommended. Fluconazole is the most common drug for treating fungal urinary tract infections. Unlike other azoles, fluconazole is available for oral administration, soluble in water, up to 80% of the drug is excreted unchanged by the kidneys, creating an effective concentration in the urine. The frequency of fluconazole-sensitive strains of fungal UTI pathogens is gradually decreasing. Therapy with fluconazole for fungal UTIs is recommended for 7–14 days. Prevention of fungal UTI in most cases does not require drug therapy. The basis for the prevention of the development of fungal UTI includes the correction of risk factors for the development of this disease: the timely removal or replacement of urinary drainage, the cessation of antibiotic therapy and the restoration of the passage of urine through the urinary tract.

Keywords: Candida, fungal infection, fluconazole, urinary tract